Abstract
In recent years much interest has been generated in using dendritic cells as vehicles for cancer immunotherapy1. This interest is based on the fact that dendritic cells function as specialized immunostimulatory cells in vivo, serving as initiators of T cell immune responses to antigen2. The dendritic cell-based approach to immunotherapy is feasible because of two advances: the identification and isolation of specific human tumor-associated antigens, and the development of techniques to propagate dendritic cells in vitro from precursor cells3,4. Hence, it is now possible to grow large numbers of dendritic cells from a patient’s blood or bone marrow in vitro, treat these cells with tumor-associated antigens, and administer to the donor with the aim of inducing a strong and therapeutic immune response to the tumor. The therapeutic efficacy of the technique has been tested in murine tumor models5, and clinical trials in cancer patients are being initiated6.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Grabbe S, Biessert S, Schwarz T, Granstein RD (1995). Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 16, 117–121.
Steinman RM (1991). The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9, 271–296.
Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J (1992). GM-CSF and TNF-a cooperate in the generation of dendritic Langerhans cells. Nature 360, 258–261.
Sallusto F, Lanzavecchia A (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J Exp Med 179, 1109–11 18.
Mayordomo Jl, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, DeLco AB, Lotze ML (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1, 1297–1302.
Hsu FJ, Bcnike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 2, 52–58.
Austyn JM, Larsen CP (1990). Migration patterns of dendritic leukocytes. Transplantation 49, 1–7.
Macatonia SE, Edwards AJ, Knight SC (1986). Dendritic cells and contact sensitivity to fluorescein isothiocyanate. Immunology 59, 509–514.
Fossum S (1988). Lymph-borne dendritic leukocytes do not recirculate, but enter the lymph node para-cortex to become interdigitating cells. Scand J Immunol 27, 97–105.
Kupiec-Weglinski JW, Austyn JM, Morris PJ (1988). Migration patterns of dendritic cells in the mouse: Traffic from the blood, and T cell-dependent and independent entry to lymphoid tissues. J Exp Med 167, 632–645.
Barratt-Boyes SM, Henderson RA, Finn OJ (1996). Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood. Immunology 87, 528–534.
Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM (1995). Dendritic cell loss from non-lymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1.1 Exp Med 181, 2237–2247.
Mai, Wang J-H, Guo Y-J, Sy M-S, Bigby M (1994). In vivo treatment with anti-ICAM-1 and anti-LFA-1 antibodies inhibits contact sensitization-induced migration of epidermal Langerhans cells to regional lymph nodes. Cell Immunol 158, 389–399.
Henderson RA, Nimgoankar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ (1996). Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 56, 3763–3770.
Austyn JM, Kupiec-Weglinski JW, Hankins DE, Morris PJ (1988). Migration patterns of dendritic cells in the mouse: Homing to T cell-dependent areas of spleen, and binding within marginal zone. 1 Exp Med 167, 646–651.
Morikawa Y, Furotani M, Kuribayashi K, Matsuura N, Kakudo K (1992). The role of antigen-presenting cells in the regulation of delayed-type hypersensitivity. I. Spleen dendritic cells. Immunology 77, 81–87.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Barratt-Boyes, S.M., Watkins, S.C., Finn, O.J. (1997). Migration of Cultured Chimpanzee Dendritic Cells Following Intravenous and Subcutaneous Injection. In: Ricciardi-Castagnoli, P. (eds) Dendritic Cells in Fundamental and Clinical Immunology. Advances in Experimental Medicine and Biology, vol 417. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9966-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9966-8_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9968-2
Online ISBN: 978-1-4757-9966-8
eBook Packages: Springer Book Archive